These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 37223116)
1. Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review. Kandula UR; Wake AD Biologics; 2023; 17():85-112. PubMed ID: 37223116 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777 [TBL] [Abstract][Full Text] [Related]
4. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473 [TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F Front Immunol; 2023; 14():1200180. PubMed ID: 37415976 [TBL] [Abstract][Full Text] [Related]
6. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications. Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796 [TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol. Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123 [TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
11. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Atluri S; Manchikanti L; Hirsch JA Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286 [TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377 [TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? Kirkham AM; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS Cytotherapy; 2023 Mar; 25(3):341-352. PubMed ID: 36333234 [TBL] [Abstract][Full Text] [Related]
16. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385 [TBL] [Abstract][Full Text] [Related]
17. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979 [TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19. Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999 [TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS Cytotherapy; 2022 Jun; 24(6):639-649. PubMed ID: 35219584 [TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]